To include your compound in the COVID-19 Resource Center, submit it here.

Revlimid misses in Phase III for follicular lymphoma

Celgene Corp. (NASDAQ:CELG) said Revlimid lenalidomide plus Rituxan rituximab missed the co-primary endpoints

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE